These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12171718)

  • 1. CD34(+) cell enrichment depletes atypical CD30(+) cells from PBPC grafts in patients with HD.
    Blystad AK; Torlakovic E; Holte H; Kvaløy S; Lenschow E; Kvalheim G
    Cytotherapy; 2001; 3(4):295-305. PubMed ID: 12171718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells.
    Blystad AK; Holte H; Kvaløy S; Smeland E; Delabie J; Kvalheim G
    Bone Marrow Transplant; 2001 Nov; 28(9):849-57. PubMed ID: 11781645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast tumor contamination of PBSC harvests: tumor depletion by positive selection of CD34(+) cells.
    Burgess J; Mills B; Griffith M; Mansour V; Weaver CH; Schwartzberg LS; Snyder EL; Krause DS; Yanovich S; Prilutskaya M; Umiel T; Moss TJ
    Cytotherapy; 2001; 3(4):285-94. PubMed ID: 12171717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD34(+) hematopoietic progenitor cell selection of bone marrow grafts for autologous transplantation in pediatric patients.
    Kasow KA; Sims-Poston L; Eldridge P; Hale GA
    Biol Blood Marrow Transplant; 2007 May; 13(5):608-14. PubMed ID: 17448921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy.
    Prince HM; Bashford J; Wall D; Rischin D; Parker N; Toner GC; Seymour JF; Blakey D; Haylock D; Simmons P; Francis P; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P
    Cytotherapy; 2002; 4(2):137-45. PubMed ID: 12006209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow versus peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphomas: different levels of tumor cell reduction. Implications for autografting.
    Lopez M; Lemoine FM; Firat H; Fouillard L; Laporte JP; Lesage S; Isnard F; Stachowiak J; Ferrer-Le Coeur F; Morel P; Najman A; Douay L; Gorin NC
    Blood; 1997 Oct; 90(7):2830-8. PubMed ID: 9326252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
    Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
    Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD34+ selection of hematopoietic blood cell collections and autotransplantation in lymphoma: overnight storage of cells at 4 degrees C does not affect outcome.
    Lazarus HM; Pecora AL; Shea TC; Koç ON; White JM; Gabriel DA; Cooper BW; Gerson SL; Krieger M; Sing AP
    Bone Marrow Transplant; 2000 Mar; 25(5):559-66. PubMed ID: 10713636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined bone marrow and peripheral blood progenitor cell autografts for patients with poor mobilization.
    Sinitsyn Y; Malone A; Mandeli J; Grosskreutz C; Osman K; Scigliano E; Shi P; Isola L
    Cytotherapy; 2009; 11(4):457-63. PubMed ID: 19499401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: comparison of T cell depletion strategies using different CD34+ selection systems or CAMPATH-1.
    Dreger P; Viehmann K; Steinmann J; Eckstein V; Müller-Ruchholtz W; Löffler H; Schmitz N
    Exp Hematol; 1995 Feb; 23(2):147-54. PubMed ID: 7530212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy.
    Blystad AK; Delabie J; Kvaløy S; Holte H; Vålerhaugen H; Ikonomou I; Kvalheim G
    Br J Haematol; 2004 Jun; 125(5):605-12. PubMed ID: 15147376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery.
    Dreger P; Viehmann K; von Neuhoff N; Glaubitz T; Petzoldt O; Glass B; Uharek L; Rautenberg P; Suttorp M; Mills B; Mitsky P; Schmitz N
    Bone Marrow Transplant; 1999 Jul; 24(2):153-61. PubMed ID: 10455343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
    Mohr M; Hilgenfeld E; Fietz T; Hoppe B; Koenigsmann M; Hoffmann M; Knauf WU; Cassens U; Sibrowski W; Kienast J; Thiel E; Berdel WE
    Clin Cancer Res; 1999 May; 5(5):1035-40. PubMed ID: 10353736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined positive and negative cell selection from allogeneic peripheral blood progenitor cells (PBPC) by use of immunomagnetic methods.
    Martín-Henao GA; Picón M; Amill B; Querol S; Ferrà C; Grañena A; García J
    Bone Marrow Transplant; 2001 Apr; 27(7):683-7. PubMed ID: 11360106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CliniMACS CD34-selected cells to support multiple cycles of high-dose therapy.
    Prince HM; Wall D; Rischin D; Toner GC; Seymour JF; Blakey D; Haylock D; Simmons P; Wolf M; Januszewicz EH; Westerman D; Richardson G; Scarlett J; Briggs P
    Cytotherapy; 2002; 4(2):147-55. PubMed ID: 12006210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer.
    Papadopoulos KP; Ayello J; Reiss RF; Troxel A; Kaufman E; Vahdat LT; Antman KH; Hesdorffer CS
    J Hematother Stem Cell Res; 1999 Aug; 8(4):357-63. PubMed ID: 10634173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma.
    Abonour R; Scott KM; Kunkel LA; Robertson MJ; Hromas R; Graves V; Lazaridis EN; Cripe L; Gharpure V; Traycoff CM; Mills B; Srour EF; Cornetta K
    Bone Marrow Transplant; 1998 Nov; 22(10):957-63. PubMed ID: 9849692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous CD34+ cell transplantation for patients with advanced lymphoma: effects of overnight storage on peripheral blood progenitor cell enrichment and engraftment.
    Koç ON; Gerson SL; Phillips GL; Cooper BW; Kutteh L; Van Zant G; Reece DE; Fox RM; Schupp JE; Tainer N; Lazarus HM
    Bone Marrow Transplant; 1998 Feb; 21(4):337-43. PubMed ID: 9509966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined positive/negative selection for highly effective purging of PBPC grafts: towards clinical application in patients with B-CLL.
    Paulus U; Schmitz N; Viehmann K; von Neuhoff N; Dreger P
    Bone Marrow Transplant; 1997 Sep; 20(5):415-20. PubMed ID: 9339759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
    Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.